RecombiMAb anti-mouse VEGF-A

About RecombiMAb anti-mouse VEGF-A

The 2G11-2A05-CP061 monoclonal antibody is a recombinant, chimeric version of the original 2G11-2A05 antibody. The variable domain sequences are identical but the constant region sequences have been switched from Rat IgG2a, κ to mouse IgG2a, κ for use in murine models. Species-matched chimeric antibodies exhibit regulated effector functions—including Fc receptor binding and complement activation—and result in less immunogenicity and formation of anti-drug antibodies (ADAs) than xenogenic antibodies in animal models. The highly controlled sequence and lack of genetic drift in recombinant antibodies provide more reliable and reproducible results over hybridoma derived antibodies. The 2G11-2A05 monoclonal antibody reacts with mouse VEGF-A (vascular endothelial growth factor A). VEGF-A is a 45 kDa homodimeric, disulfide-linked glycoprotein that plays key roles in angiogenesis, vasculogenesis, and endothelial cell growth. It promotes mitogenesis, chemotaxis, and vascular permeability. Most tumors have a requirement for angiogenesis, and inhibition of VEGF binding to VEGF receptors has been the focus of several tumor therapeutic strategies. The 2G11-2A05 antibody neutralizes the biological activity of VEGF-A.